Moderna’s updated COVID-19 booster shot shows even more efficiency against variants, the pharmaceutical company announced Tuesday, citing preliminary results from a trial.
The bivalent mRNA booster, a combo shot that targets the beta variant of COVID-19 as well as the original version of the disease, “demonstrated superiority” against beta, delta and omicron variants after one month and still attacked the omicron variant after six months, according to Moderna. Those who were given the shot that also targeted beta saw more than twice the level of antibodies against the omicron variant as the current shot on the market.
Moderna is also currently testing a bivalent shot that targets omicron, with results expected in June.
